Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) COO Sells $51,538.90 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) COO Donald Notman sold 6,035 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $8.54, for a total transaction of $51,538.90. Following the completion of the sale, the chief operating officer owned 377,802 shares of the company’s stock, valued at approximately $3,226,429.08. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Donald Notman also recently made the following trade(s):

• On Monday, February 2nd, Donald Notman sold 5,455 shares of Ocular Therapeutix stock. The stock was sold at an average price of $9.14, for a total value of $49,858.70.

Ocular Therapeutix Stock Up 2.8%

NASDAQ:OCUL opened at $9.16 on Friday. Ocular Therapeutix, Inc. has a 1 year low of $5.78 and a 1 year high of $16.44. The stock has a 50-day moving average price of $11.82 and a two-hundred day moving average price of $11.93. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -6.36 and a beta of 0.90. The company has a current ratio of 7.85, a quick ratio of 7.78 and a debt-to-equity ratio of 0.27.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.05. Ocular Therapeutix had a negative return on equity of 94.79% and a negative net margin of 511.90%.The company had revenue of $13.25 million for the quarter. During the same period in the prior year, the business earned ($0.29) EPS. The company’s revenue for the quarter was down 22.4% compared to the same quarter last year. As a group, equities analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Ocular Therapeutix

A number of institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 893 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Ocular Therapeutix by 1.8% during the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 1,314 shares during the period. Nisa Investment Advisors LLC raised its holdings in Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,392 shares in the last quarter. Trust Co. of Vermont raised its stake in Ocular Therapeutix by 24.3% in the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,750 shares in the last quarter. Finally, Profund Advisors LLC boosted its position in shares of Ocular Therapeutix by 9.9% during the 3rd quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 2,272 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OCUL. HC Wainwright upped their price target on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the company a “buy” rating in a report on Monday, December 8th. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday. TD Cowen reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, December 9th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ocular Therapeutix has an average rating of “Moderate Buy” and a consensus price target of $24.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.